SEC Comment Letter 0000000000-23-003709 to Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX)
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: April 13, 2023 · CIK: 0001534120 · Accession: 0000000000-23-003709
AI Filing Summary & Sentiment
File numbers found in text: 333-271225
Letter
United States securities and exchange commission logo April 13, 2023 Christopher Sullivan Chief Financial Officer Avalo Therapeutics, Inc. 540 Gaither Road, Suite 400 Rockville, Maryland 20850 Re:Avalo Therapeutics, Inc. Registration Statement on Form S-3 Filed April 12, 2023 File No. 333-271225 Dear Christopher Sullivan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew J. Gibbons
Show Raw Text
United States securities and exchange commission logo
April 13, 2023
Christopher Sullivan
Chief Financial Officer
Avalo Therapeutics, Inc.
540 Gaither Road, Suite 400
Rockville, Maryland 20850
Re:Avalo Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 12, 2023
File No. 333-271225
Dear Christopher Sullivan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew J. Gibbons